Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synchrovax SEM Vaccine in Stage IV Melanoma
NCT00033228Phase 2Completed
- Sponsor
- MannKind
- Start
- Jan 2002
- Primary completion
- Mar 2003
- Modality
- Prophylactic Vaccines, Peptides, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of MKC1106-MT in melanoma, sponsored by MannKind. Started Jan 2002; status: completed.
02
Drugs
MKC1106-MT
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00033228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00033228.